India/United Kingdom,
2022-03-30 19:09
(813 d 01:33 ago)

(edited by dshah on 2022-03-31 11:42)
Posting: # 22889
Views: 2,319

 Bempedoic Acid TBM BE study in SBOA [BE/BA News]

Hello All!

I was going through SBOA of Bempedoic acid marketed as Nexleton tablets.
In general, a BE study of Phase III vs TBM formulation can suffice the need for clinical significance. But in what condition, FDA can waive such condition of BE of TBM formulation with Phase III formulations in IND filing? [image]
or considering the biopharmaceutics risk assessment- it is a low risk and study can be waived?
Divyen Shah

2022-03-31 10:43
(812 d 09:58 ago)

@ dshah
Posting: # 22890
Views: 1,945

 Bempedoic Acid TBM BE study in SBOA

I heard from a change in the shape of the tablet will raise question as well.
UA Flag
 Admin contact
23,059 posts in 4,841 threads, 1,646 registered users;
26 visitors (0 registered, 26 guests [including 6 identified bots]).
Forum time: 20:42 CEST (Europe/Vienna)

Friends don’t let friends use Excel for statistics!    Jonathan D. Cryer

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz